Compare INMD & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMD | BCX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.0M | 930.9M |
| IPO Year | 2018 | N/A |
| Metric | INMD | BCX |
|---|---|---|
| Price | $14.14 | $12.17 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $16.17 | N/A |
| AVG Volume (30 Days) | ★ 373.1K | 138.5K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.72 | $9.69 |
| 52 Week High | $16.67 | $13.86 |
| Indicator | INMD | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 48.52 |
| Support Level | $13.79 | $11.90 |
| Resistance Level | $14.18 | $12.25 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 35.80 | 73.33 |
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies, or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.